BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474-502. [DOI: 10.1038/s41569-020-0348-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 36.5] [Reference Citation Analysis]
Number Citing Articles
1 Cignarella A, Fadini GP, Bolego C, Trevisi L, Boscaro C, Sanga V, Seccia TM, Rosato A, Rossi GP, Barton M. Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. Cardiovasc Res 2021:cvab096. [PMID: 33739385 DOI: 10.1093/cvr/cvab096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zheng JY, Mixon AC, McLarney MD. Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review. Curr Phys Med Rehabil Rep 2021;:1-12. [PMID: 34178432 DOI: 10.1007/s40141-021-00312-9] [Reference Citation Analysis]
3 Boddicker NJ, Larson MC, Castellino A, Herrmann J, Inwards DJ, Thanarajasingam G, Maurer MJ, Allmer C, Witzig TE, Nowakowski GS, Habermann TM, Villarraga HR, Slager SL, Cerhan JR, Thompson CA. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol 2021;96:979-88. [PMID: 33971040 DOI: 10.1002/ajh.26230] [Reference Citation Analysis]
4 Choksey A, Timm KN. Cancer Therapy-Induced Cardiotoxicity-A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. Int J Mol Sci 2021;23:441. [PMID: 35008867 DOI: 10.3390/ijms23010441] [Reference Citation Analysis]
5 Hou K, Shen J, Yan J, Zhai C, Zhang J, Pan JA, Zhang Y, Jiang Y, Wang Y, Lin RZ, Cong H, Gao S, Zong WX. Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine 2021;69:103456. [PMID: 34233258 DOI: 10.1016/j.ebiom.2021.103456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bravo-jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion in Cardiology 2020;35:531-7. [DOI: 10.1097/hco.0000000000000767] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Chen R, Peng L, Qiu Z, Wang Y, Wei F, Zhou M, Zhu F. Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. Front Cardiovasc Med 2021;8:727445. [PMID: 34938778 DOI: 10.3389/fcvm.2021.727445] [Reference Citation Analysis]
8 Ruddy KJ, Patel SR, Higgins AS, Armenian SH, Herrmann J. Cardiovascular Health during and after Cancer Therapy. Cancers (Basel) 2020;12:E3737. [PMID: 33322622 DOI: 10.3390/cancers12123737] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Stein-Merlob AF, Rothberg MV, Ribas A, Yang EH. Cardiotoxicities of novel cancer immunotherapies. Heart 2021:heartjnl-2020-318083. [PMID: 33722826 DOI: 10.1136/heartjnl-2020-318083] [Reference Citation Analysis]
10 Addison D, Campbell CM, Guha A, Ghosh AK, Dent SF, Jneid H. Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond. J Am Heart Assoc 2020;9:e017787. [PMID: 32713239 DOI: 10.1161/JAHA.120.017787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, Fauchier L. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer 2021;127:2122-9. [PMID: 33631041 DOI: 10.1002/cncr.33470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Fonseca M, Cheng E, Do D, Haldar S, Kutty S, Yang EH, Ghosh AK, Guha A. Bradyarrhythmias in Cardio-Oncology. South Asian J Cancer 2021;10:195-210. [PMID: 34966697 DOI: 10.1055/s-0041-1731907] [Reference Citation Analysis]
13 Florczak A, Grzechowiak I, Deptuch T, Kucharczyk K, Kaminska A, Dams-Kozlowska H. Silk Particles as Carriers of Therapeutic Molecules for Cancer Treatment. Materials (Basel) 2020;13:E4946. [PMID: 33158060 DOI: 10.3390/ma13214946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lind L, Araujo JA, Barchowsky A, Belcher S, Berridge BR, Chiamvimonvat N, Chiu WA, Cogliano VJ, Elmore S, Farraj AK, Gomes AV, McHale CM, Meyer-Tamaki KB, Posnack NG, Vargas HM, Yang X, Zeise L, Zhou C, Smith MT. Key Characteristics of Cardiovascular Toxicants. Environ Health Perspect 2021;129:95001. [PMID: 34558968 DOI: 10.1289/EHP9321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cheng D, Liu P, Wang Z. Palmatine attenuates the doxorubicin-induced inflammatory response, oxidative damage and cardiomyocyte apoptosis. Int Immunopharmacol 2022;106:108583. [PMID: 35151220 DOI: 10.1016/j.intimp.2022.108583] [Reference Citation Analysis]
16 Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2021:ehab674. [PMID: 34904661 DOI: 10.1093/eurheartj/ehab674] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ramai D, Heaton J, Ghidini M, Chandan S, Barakat M, Dhindsa B, Dhaliwal A, Facciorusso A. Population-Based Long-term Cardiac-Specific Mortality Among Patients With Major Gastrointestinal Cancers. JAMA Netw Open 2021;4:e2112049. [PMID: 34137831 DOI: 10.1001/jamanetworkopen.2021.12049] [Reference Citation Analysis]
18 Keramida K, Filippatos G, Farmakis D. Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. Eur Heart J Cardiovasc Pharmacother 2021;7:321-3. [PMID: 32633808 DOI: 10.1093/ehjcvp/pvaa059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sase K, Fujisaka Y, Shoji M, Mukai M. Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Curr Treat Options Oncol 2021;22:71. [PMID: 34110522 DOI: 10.1007/s11864-021-00869-6] [Reference Citation Analysis]
20 Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology 2020;9:1796002. [PMID: 32934889 DOI: 10.1080/2162402X.2020.1796002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
21 Romitan DM, Rădulescu D, Berindan-Neagoe I, Stoicescu L, Grosu A, Rădulescu L, Gulei D, Ciuleanu TE. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines 2020;8:E496. [PMID: 33198152 DOI: 10.3390/biomedicines8110496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tvedt THA, Vo AK, Bruserud Ø, Reikvam H. Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. J Clin Med 2021;10:5190. [PMID: 34768710 DOI: 10.3390/jcm10215190] [Reference Citation Analysis]
23 Nijst P, Tang WHW. Managing Cancer Patients and Survivors With Advanced Heart Failure. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00953-y] [Reference Citation Analysis]
24 Zhou W, Cheng Y, Zhu P, Nasser MI, Zhang X, Zhao M. Implication of Gut Microbiota in Cardiovascular Diseases. Oxid Med Cell Longev 2020;2020:5394096. [PMID: 33062141 DOI: 10.1155/2020/5394096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021;8:e001849. [PMID: 34952868 DOI: 10.1136/openhrt-2021-001849] [Reference Citation Analysis]
26 Anani T, Rahmati S, Sultana N, David AE. MRI-traceable theranostic nanoparticles for targeted cancer treatment. Theranostics 2021;11:579-601. [PMID: 33391494 DOI: 10.7150/thno.48811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
27 Montisci A, Palmieri V, Liu JE, Vietri MT, Cirri S, Donatelli F, Napoli C. Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission. Front Cardiovasc Med 2021;8:713694. [PMID: 34540917 DOI: 10.3389/fcvm.2021.713694] [Reference Citation Analysis]
28 Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G. The cancer patient and cardiology. Eur J Heart Fail 2020;22:2290-309. [PMID: 32809231 DOI: 10.1002/ejhf.1985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
29 Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021. [PMID: 34196077 DOI: 10.1002/ejhf.2289] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Nishi M, Wang PY, Hwang PM. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy. Arterioscler Thromb Vasc Biol 2021;41:2648-60. [PMID: 34587760 DOI: 10.1161/ATVBAHA.121.316697] [Reference Citation Analysis]
31 Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 2022;10:540. [DOI: 10.3390/vaccines10040540] [Reference Citation Analysis]
32 Vasileiou PVS, Siasos G, Gorgoulis VG. Molecular biomarkers in cardio-oncology: Where we stand and where we are heading. Bioessays 2022;:e2100234. [PMID: 35352831 DOI: 10.1002/bies.202100234] [Reference Citation Analysis]
33 Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest 2021;131:145186. [PMID: 33645548 DOI: 10.1172/JCI145186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
34 Broberg AM, Geisler J, Tuohinen S, Skytta T, Hrafnkelsdóttir ÞJ, Nielsen KM, Hedayati E, Omland T, Offersen BV, Lyon AR, Gulati G. Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. Curr Heart Fail Rep 2020;17:397-408. [PMID: 32979150 DOI: 10.1007/s11897-020-00486-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Florczak A, Deptuch T, Lewandowska A, Penderecka K, Kramer E, Marszalek A, Mackiewicz A, Dams-Kozlowska H. Functionalized silk spheres selectively and effectively deliver a cytotoxic drug to targeted cancer cells in vivo. J Nanobiotechnology 2020;18:177. [PMID: 33261651 DOI: 10.1186/s12951-020-00734-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Yang Z, Wang W, Wang X, Qin Z. Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Front Pharmacol 2021;12:741451. [PMID: 34790121 DOI: 10.3389/fphar.2021.741451] [Reference Citation Analysis]
37 Safi M, Kanesvaran R, Alradhi M, Al-Danakh A, Ping F, Al-Sabai N, Shan X, Liu J. Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study. Front Oncol 2020;10:572380. [PMID: 33194672 DOI: 10.3389/fonc.2020.572380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Mehran R, Cao D, Baber U. Ticagrelor in Patients With Cancer: 2 Birds With 1 Stone. JACC CardioOncol 2020;2:251-3. [PMID: 34396234 DOI: 10.1016/j.jaccao.2020.05.002] [Reference Citation Analysis]
39 Li W, Liu M, Yu F, Jiang T, Zhu W, Liu H. Changes in epicardial adipose tissue among women treated with trastuzumab for breast cancer. Int J Cardiol 2021:S0167-5273(21)01998-7. [PMID: 34890762 DOI: 10.1016/j.ijcard.2021.12.006] [Reference Citation Analysis]
40 Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer 2020;147:3160-7. [DOI: 10.1002/ijc.33119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Parrotta EI, Lucchino V, Scaramuzzino L, Scalise S, Cuda G. Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges. Int J Mol Sci 2020;21:E4354. [PMID: 32575374 DOI: 10.3390/ijms21124354] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
42 Arangalage D, Degrauwe N, Michielin O, Monney P, Özdemir BC. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treat Rev 2021;100:102282. [PMID: 34438238 DOI: 10.1016/j.ctrv.2021.102282] [Reference Citation Analysis]
43 Tosca EM, Bartolucci R, Magni P, Poggesi I. Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. Expert Opin Drug Discov 2021;:1-26. [PMID: 34181496 DOI: 10.1080/17460441.2021.1931114] [Reference Citation Analysis]
44 Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G, Nattel S. The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nat Rev Cardiol 2021. [PMID: 34667279 DOI: 10.1038/s41569-021-00624-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Cartas-Espinel I, Telechea-Fernández M, Manterola Delgado C, Ávila Barrera A, Saavedra Cuevas N, Riffo-Campos AL. Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review. ESC Heart Fail 2022. [PMID: 35261178 DOI: 10.1002/ehf2.13735] [Reference Citation Analysis]
46 Jiang L, Gong Y, Hu Y, You Y, Wang J, Zhang Z, Wei Z, Tang C. Peroxiredoxin-1 Overexpression Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Oxidative Stress and Cardiomyocyte Apoptosis. Oxid Med Cell Longev 2020;2020:2405135. [PMID: 32802259 DOI: 10.1155/2020/2405135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Yan W, Zhang Z. Online Automatic Diagnosis System of Cardiac Arrhythmias Based on MIT-BIH ECG Database. J Healthc Eng 2021;2021:1819112. [PMID: 34956556 DOI: 10.1155/2021/1819112] [Reference Citation Analysis]
48 Yin Y, Shen H. Advances in Cardiotoxicity Induced by Altered Mitochondrial Dynamics and Mitophagy. Front Cardiovasc Med 2021;8:739095. [PMID: 34616789 DOI: 10.3389/fcvm.2021.739095] [Reference Citation Analysis]
49 Muhammad RN, Sallam N, El-Abhar HS. Activated ROCK/Akt/eNOS and ET-1/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin. Sci Rep 2020;10:14693. [PMID: 32895407 DOI: 10.1038/s41598-020-71531-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Stein-Merlob AF, Hsu JJ, Colton B, Berg CJ, Ferreira A, Price MM, Wainberg Z, Baas AS, Deng MC, Parikh RV, Yang EH. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery. ESC Heart Fail 2021. [PMID: 34390221 DOI: 10.1002/ehf2.13545] [Reference Citation Analysis]
51 Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, Patton KK, Singh JP, Olshansky B. Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation 2021;144:e41-55. [PMID: 34134525 DOI: 10.1161/CIR.0000000000000986] [Reference Citation Analysis]
52 Sundaram A, Peng L, Chai L, Xie Z, Ponraj JS, Wang X, Wang G, Zhang B, Nie G, Xie N, Rajesh Kumar M, Zhang H. Advanced nanomaterials for hypoxia tumor therapy: challenges and solutions. Nanoscale 2020;12:21497-518. [DOI: 10.1039/d0nr06271e] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Fraley C, Milgrom SA, Kondapalli L, Taylor MRG, Mestroni L, Miyamoto SD. Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy. Children (Basel) 2021;8:829. [PMID: 34572260 DOI: 10.3390/children8090829] [Reference Citation Analysis]
54 Zhu H, Ivanovic M, Nguyen A, Nguyen PK, Wu SM. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. J Mol Cell Cardiol 2021;160:121-7. [PMID: 34303670 DOI: 10.1016/j.yjmcc.2021.07.006] [Reference Citation Analysis]
55 Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947-59. [PMID: 34453829 DOI: 10.1093/ehjacc/zuab056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Qiu S, Zhou T, Qiu B, Zhang Y, Zhou Y, Yu H, Zhang J, Liu L, Yuan L, Yang G, Duan Y, Xing C. Risk Factors for Anthracycline-Induced Cardiotoxicity. Front Cardiovasc Med 2021;8:736854. [PMID: 34660739 DOI: 10.3389/fcvm.2021.736854] [Reference Citation Analysis]
57 Chang EK, Chanson D, Teh JB, Iukuridze A, Peng K, Forman SJ, Nakamura R, Wong FL, Cai L, Armenian SH. Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. J Clin Oncol 2021;39:902-10. [PMID: 33417479 DOI: 10.1200/JCO.20.02401] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wang Y, Wang Y, Han X, Sun J, Li C, Adhikari BK, Zhang J, Miao X, Chen Z. Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer. Front Cardiovasc Med 2022;9:727487. [DOI: 10.3389/fcvm.2022.727487] [Reference Citation Analysis]
59 Palaskas NL, Lopez-Mattei J. The Role of Echocardiography in the Cancer Patient. Curr Cardiol Rep 2020;22:103. [PMID: 32770406 DOI: 10.1007/s11886-020-01373-3] [Reference Citation Analysis]
60 Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin 2020;70:480-504. [PMID: 32910493 DOI: 10.3322/caac.21635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
61 Wang Y, Yin X, Liang X, Chen Y, Pan S, Chen Z, Tse G, Geng X, Liu T. Three-dimensional vectorcardiographic characteristics of breast cancer patients treated with chemotherapy. J Electrocardiol 2021;67:23-30. [PMID: 34000614 DOI: 10.1016/j.jelectrocard.2021.04.018] [Reference Citation Analysis]
62 Chen D, Kelly C, Haw TJ, Lombard JM, Nordman IIC, Croft AJ, Ngo DTM, Sverdlov AL. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers. Curr Heart Fail Rep 2021;18:362-77. [PMID: 34731413 DOI: 10.1007/s11897-021-00535-w] [Reference Citation Analysis]
63 Li S, Xu Z, Guo M, Li M, Wen Z. Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management. Drug Discov Today 2021:S1359-6446(21)00447-5. [PMID: 34718206 DOI: 10.1016/j.drudis.2021.10.009] [Reference Citation Analysis]
64 Avagimyan AA, Mkrtchyan LH, Gevorkyan AA, Kononchuk NB, Kakturskiy LV, Djndoyan ZT. Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:785-91. [DOI: 10.20996/1819-6446-2021-10-17] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Dong S, Luo C, Hu X, Zhang J, Cai Q, Qian Y, Ran F, Ou W, Wang J, Huang Q, Ren T, Han G, Zhang F, Wei W, Liang X, Xu H, Wang S, Shi L, Wei S, Hu S. Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. Front Oncol 2020;10:1555. [PMID: 33014801 DOI: 10.3389/fonc.2020.01555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Guo F, Hall AR, Tape CJ, Ling S, Pointon A. Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology. Trends Pharmacol Sci 2021;42:675-87. [PMID: 34092416 DOI: 10.1016/j.tips.2021.05.004] [Reference Citation Analysis]
67 Scott EN, Hasbullah JS, Carleton BC, Ross CJD. Prevention of adverse drug effects: a pharmacogenomic approach. Curr Opin Pediatr 2020;32:646-53. [PMID: 32796162 DOI: 10.1097/MOP.0000000000000935] [Reference Citation Analysis]
68 Giannopoulou AF, Velentzas AD, Anagnostopoulos AK, Agalou A, Papandreou NC, Katarachia SA, Koumoundourou DG, Konstantakou EG, Pantazopoulou VI, Delis A, Michailidi MT, Valakos D, Chatzopoulos D, Syntichaki P, Iconomidou VA, Tsitsilonis OE, Papassideri IS, Voutsinas GE, Hatzopoulos P, Thanos D, Beis D, Anastasiadou E, Tsangaris GT, Stravopodis DJ. From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers (Basel) 2021;13:2024. [PMID: 33922182 DOI: 10.3390/cancers13092024] [Reference Citation Analysis]
69 Yu C, Pathan F, Tan TC, Negishi K. The Utility of Advanced Cardiovascular Imaging in Cancer Patients-When, Why, How, and the Latest Developments. Front Cardiovasc Med 2021;8:728215. [PMID: 34540922 DOI: 10.3389/fcvm.2021.728215] [Reference Citation Analysis]
70 Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A, Diemberger I. The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Curr Heart Fail Rep 2020;17:365-83. [PMID: 33025463 DOI: 10.1007/s11897-020-00485-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
71 Cehic DA, Sverdlov AL, Koczwara B, Emery J, Ngo DTM, Thornton-Benko E. The Importance of Primary Care in Cardio-Oncology. Curr Treat Options Oncol 2021;22:107. [PMID: 34674055 DOI: 10.1007/s11864-021-00908-2] [Reference Citation Analysis]
72 Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;17:503-22. [DOI: 10.1038/s41569-020-0347-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
73 Castrillon JA, Eng C, Cheng F. Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Hum Mol Genet 2020;29:R186-96. [PMID: 32620943 DOI: 10.1093/hmg/ddaa137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Papazoglou P, Peng L, Sachinidis A. Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs. Front Cardiovasc Med 2021;8:658900. [PMID: 33987212 DOI: 10.3389/fcvm.2021.658900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Goldman A, Bomze D, Dankner R, Fourey D, Boursi B, Arad M, Maor E. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. Target Oncol 2021;16:471-83. [PMID: 33970401 DOI: 10.1007/s11523-021-00817-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Ferrari E, Rasponi M. Liver-Heart on chip models for drug safety. APL Bioeng 2021;5:031505. [PMID: 34286172 DOI: 10.1063/5.0048986] [Reference Citation Analysis]
77 Wu H, Jiang Q, Luo K, Zhu C, Xie M, Wang S, Fei Z, Zhao J. Synthesis of iridium-based nanocomposite with catalase activity for cancer phototherapy. J Nanobiotechnology 2021;19:203. [PMID: 34233696 DOI: 10.1186/s12951-021-00948-8] [Reference Citation Analysis]
78 Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep 2021;23:11. [PMID: 33483873 DOI: 10.1007/s11886-021-01440-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Liu Q, Yu Y, Lin J, Wang Y, Ai L, Li Q, Wu W, Jin H, Li S, Liu M, Yu S, Liu T. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. Eur J Cancer 2021;157:10-20. [PMID: 34464781 DOI: 10.1016/j.ejca.2021.07.023] [Reference Citation Analysis]
80 Yeh CF, Chin YC, Hung W, Huang PI, Lan MY. Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma. Support Care Cancer 2022. [PMID: 35357575 DOI: 10.1007/s00520-022-07011-8] [Reference Citation Analysis]
81 Heusch G. Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 2022;117:1. [PMID: 35024969 DOI: 10.1007/s00395-022-00909-8] [Reference Citation Analysis]
82 Ohman RE, Yang EH, Abel ML. Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes. J Am Heart Assoc 2021;10:e023852. [PMID: 34913366 DOI: 10.1161/JAHA.121.023852] [Reference Citation Analysis]
83 Abe JI, Yusuf SW, Deswal A, Herrmann J. Cardio-Oncology: Learning From the Old, Applying to the New. Front Cardiovasc Med 2020;7:601893. [PMID: 33324688 DOI: 10.3389/fcvm.2020.601893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Jafari L, Akhter N. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review. Breast Cancer Res Treat 2021;186:295-303. [PMID: 33481134 DOI: 10.1007/s10549-021-06096-9] [Reference Citation Analysis]
85 Szabó Z, Hornyák L, Miskei M, Székvölgyi L. Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity. Front Pharmacol 2020;11:569955. [PMID: 33643029 DOI: 10.3389/fphar.2020.569955] [Reference Citation Analysis]
86 Monahan DS, Almas T, Wyile R, Cheema FH, Duffy GP, Hameed A. Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. Drug Deliv Transl Res 2021;11:1924-42. [PMID: 33449342 DOI: 10.1007/s13346-020-00885-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol 2021;:100909. [PMID: 34167841 DOI: 10.1016/j.cpcardiol.2021.100909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Su X, Zhang X, Liu W, Yang X, An N, Yang F, Sun J, Xing Y, Shang H. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin Cancer Biol 2021:S1044-579X(21)00215-7. [PMID: 34375726 DOI: 10.1016/j.semcancer.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Borges GSM, Lages EB, Sicard P, Ferreira LAM, Richard S. Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies. Front Cardiovasc Med 2021;8:690533. [PMID: 34277738 DOI: 10.3389/fcvm.2021.690533] [Reference Citation Analysis]
90 Doukas PG, Patel RN, Venkatesh V, Khan SS, Baldridge A, Akhter N. Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic. Breast Cancer Res Treat 2021. [PMID: 34390418 DOI: 10.1007/s10549-021-06353-x] [Reference Citation Analysis]
91 Kang W, Ji Y, Cheng Y. Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy. Int J Pharm 2021;603:120691. [PMID: 33965541 DOI: 10.1016/j.ijpharm.2021.120691] [Reference Citation Analysis]
92 Guan J, Zhang M. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer. Oncol Lett 2021;21:100. [PMID: 33376533 DOI: 10.3892/ol.2020.12361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Xia W, Tao Z, Zhu B, Zhang W, Liu C, Chen S, Song M. Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. Int J Mol Sci 2021;22:9118. [PMID: 34502028 DOI: 10.3390/ijms22179118] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]